Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Encaleret - BridgeBio Pharma

Next Previous
Drug Profile

Encaleret - BridgeBio Pharma

Alternative Names: BBP-305; CLTX-305; Encaleret Sulfate

Latest Information Update: 29 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Calcilytix therapeutix
  • Developer BridgeBio Pharma; Calcilytix Therapeutics
  • Class Amines; Benzoic acids; Calcium regulators; Ethers; Halogenated hydrocarbons; Osteoporosis therapies; Small molecules
  • Mechanism of Action Calcium-sensing receptor antagonists; Osteogenesis stimulants; Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypocalcaemia; Hypoparathyroidism
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypocalcaemia; Hypoparathyroidism

Most Recent Events

  • 23 Jul 2025 Calcilytix Therapeutics plans a phase II/III trial for Hypocalcaemia (In children, In adolescent, In infants, In neonates) in August 2025 (PO, Tablet) (NCT07080385)
  • 23 Jul 2025 BridgeBio Pharma plans a registrational trial in Hypoparathyroidism in 2026
  • 13 Jan 2025 Calcilytix Therapeutics completes enrolment in the phase III CALIBRATE trial for Hypocalcaemia (Treatment-experienced, In adolescents, In adults) in USA, Australia, Czech Republic, Canada, Denmark, France, Italy, Japan, the Netherlands, and the UK (PO) (NCT05680818)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top